1352151-70-2

Upstream product

• 103882-09-3 N-Boc-4-I-Phe-OH 
• 1254318-97-2 (S)-2-amino-3-(4'-cyanobiphenyl-4-yl)propanamide 
• 115951-16-1 1-tert-butoxycarbonylaminocyclohexanecarboxylic acid 
• 868694-44-4 [(1S)-1-carbamoyl-2-(4-iodophenyl)ethyl]carbamic acid tert-butyl ester 
• 1254318-96-1 (S)-tert-butyl (1-amino-3-(4'-cyano-[1,1'-biphenyl]-4-yl)-1-oxopropan-2-yl)carbamate 

Downstream Products

• 1352151-68-8 (S)-1-amino-N-(1-cyano-2-(4'-cyanobiphenyl-4-yl)ethyl)cyclohexanecarboxamide 
• 1352151-71-3 (S)-tert-butyl 1-(1-cyano-2-(4'-cyanobiphenyl-4-yl)ethylcarbamoyl)cyclohexylcarbamate 
• 1352151-69-9 (S)-1-amino-N-(1-cyano-2-(4'-cyanobiphenyl-4-yl)ethyl)cyclohexanecarboxamide trifluoroacetate 

Relevant academic research and scientific papers

Cathepsin C inhibitors: Property optimization and identification of a clinical candidate

A lead generation and optimization program delivered the highly selective and potent CatC inhibitor 10 as an in vivo tool compound and potential development candidate. Structural studies were undertaken to generate SAR understanding.

SUBSTITUTED N-[1-CYANO-2-(PHENYL)ETHYL] 1-AMINOCYCLOALK-1-YLCARBOXAMIDE COMPOUNDS - 760

The present invention provides compounds of formula (I) in which, n, R1, R2 and Q are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.